Publications by authors named "Aina Karen Anthi"
Monoclonal IgG antibodies constitute the fastest growing class of therapeutics. Thus, there is an intense interest to design more potent antibody formats, where long plasma half-life is a commercially competitive differentiator affecting dosing, frequency of administration and thereby potentially patient compliance. Here, we report on an Fc-engineered variant with three amino acid substitutions Q311R/M428E/N434W (REW), that enhances plasma half-life and mucosal distribution, as well as allows for needle-free delivery across respiratory epithelial barriers in human FcRn transgenic mice.
View Article and Find Full Text PDFArticle Synopsis
- - Immunocompromised patients struggle to build strong vaccine-induced immunity against emerging SARS-CoV-2 variants, particularly the Omicron subvariants, highlighting the need for new treatment methods.
- - Researchers have developed a long-acting viral entry-blocking molecule by fusing a modified ACE2 variant with human albumin to improve stability and binding to the virus.
- - This engineered ACE2-albumin fusion shows strong effectiveness in neutralizing SARS-CoV-2 variants and can be delivered through non-invasive nasal administration, providing a promising alternative to traditional treatments.
The neonatal Fc receptor (FcRn) was first recognized for its role in transfer of maternal IgG to the foetus or newborn, providing passive immunity early in life. However, it has become clear that the receptor is versatile, widely expressed and plays an indispensable role in both immunological and non-immunological processes throughout life. The receptor rescues immunoglobulin G (IgG) and albumin from intracellular degradation and shuttles the ligands across polarized cell barriers, in all cases via a pH-dependent binding-and-release mechanism.
View Article and Find Full Text PDF